Form 8-K - Current report:
SEC Accession No. 0001628280-22-003178
Filing Date
2022-02-18
Accepted
2022-02-18 16:01:38
Documents
16
Period of Report
2022-02-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20220214.htm   iXBRL 8-K 58103
2 EX-10.1 ex-101neilea.htm EX-10.1 20107
3 EX-10.2 ex-102sullivanea.htm EX-10.2 22953
4 EX-99.1 ex-991pressrelease02172022.htm EX-99.1 15830
8 GRAPHIC avalologo.jpg GRAPHIC 8535
  Complete submission text file 0001628280-22-003178.txt   285980

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20220214.xsd EX-101.SCH 1979
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20220214_lab.xml EX-101.LAB 24319
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20220214_pre.xml EX-101.PRE 12712
10 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20220214_htm.xml XML 10017
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 22652601
SIC: 2834 Pharmaceutical Preparations